Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system.
Smilow Cancer center at Yale New Haven Hospital, CT, USA Groupe Francophone des myélodysplasies, Hopital Saint Louis, Paris, France thomas.prebet@yale.edu.
Thomas
T
Prebet
Groupe Francophone des myélodysplasies, Hopital Saint Louis, Paris, France Service Hematologie Senior, Hopital Saint Louis, Paris, France.
Pierre
P
Fenaux
Groupe Francophone des myélodysplasies, Hopital Saint Louis, Paris, France Service Hematologie 2, Institut Paoli-Calmettes, Marseille, France.
Norbert
N
Vey
D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D001374:Azacitidine / Q000627:therapeutic use*; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000175:diagnosis* / Q000188:drug therapy* / Q000401:mortality; D009656:North America / Q000453:epidemiology; D011237:Predictive Value of Tests; D015203:Reproducibility of Results; D012720:Severity of Illness Index; D017211:Treatment Failure; D016896:Treatment Outcome
D000964:Antimetabolites, Antineoplastic; D001374:Azacitidine
acute myeloid leukemia; cytogenics and molecular genetics; hypomethylating agents; melodysplastic syndromes; stem cell transplantation
Haematologica. 2013 Feb;98(2):e18-9
22983576
J Clin Oncol. 2011 Aug 20;29(24):3322-7
21788559
Lancet Oncol. 2009 Mar;10(3):223-32
19230772
Haematologica. 2016 Jun;101(6):e224-7
26992944
Cancer. 2006 Apr 15;106(8):1794-803
16532500
Blood. 2012 Sep 20;120(12):2454-65
22740453
Br J Haematol. 2012 Jun;157(6):764-6
22390719